Advertisement
News
Advertisement

Syndax scores EU patent for potential cancer therapeutic

Wed, 08/17/2011 - 10:40am
Mass High Tech: The Journal of New England Technology

Syndax Pharmaceuticals Inc., a cancer therapeutics developer in Waltham, has been granted a patent from the European Patent Office for an oral HDAC inhibitor, called entinostat, to treat metastatic breast cancer and advanced non-small cell lung cancer. The U.S. patent office granted the company a patent for entinostat in June.

Entinostat is a novel, oral small molecule inhibitor of class I histone deacetylases (HDAC).

SOURCE

Advertisement

Share this Story

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading